Seres Therapeutics (MCRB) executive compensation, 2026 proxy

Thomas J. DesRosier, Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer, was paid $1.1M in 2025, down 9% from $1.2M the year before.

Filed
April 27, 2026
Annual meeting
June 9, 2026
Pay year
2025
Named executives
5
CEO total pay
$1.1M-9% vs prior year
Prior say-on-pay support
64%of votes cast
Appointment Bonus
$500,000Paid to co-CEOs upon appointment
Say-on-Pay Support
64%Support at 2025 annual meeting

How DesRosier was paid

$1.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary45%Bonus15%Option awards39%All other compensation1%

Named executive officers

ExecutiveTotal
Eric D. ShaffFormer President and Chief Executive Officer$1,775,549
Thomas J. DesRosierFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer$1,136,023
Marella ThorellFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer$1,113,396
Matthew Henn, Ph.D.President and Chief Scientific Officer$1,014,347
Teresa L. Young, Ph.D.Former Executive Vice President and Chief Commercial and Strategy Officer$1,021,462

What changed and why

  • Eric D. Shaff resigned as President and Chief Executive Officer effective July 31, 2025.
  • Thomas J. DesRosier and Marella Thorell were appointed as Co-Presidents and Co-Chief Executive Officers effective August 1, 2025.
  • $500KTransition letters provided cash appointment bonuses equal to $500,000 for Mr. DesRosier and Ms. Thorell.
  • Stockholders approved the 2025 Incentive Award Plan to replace the prior 2015 Plan.
  • 64%Approximately 64 percent of votes cast supported the say-on-pay proposal at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.